Publication:
Spirotetronate antibiotics with anti-Clostridium activity from Actinomadura sp. 2EPS

Simple item page
dc.contributor.authorJirayut Euanorasetren_US
dc.contributor.authorBungonsiri Intraen_US
dc.contributor.authorPhayungsak Mongkolen_US
dc.contributor.authorSurang Chankhamhaengdechaen_US
dc.contributor.authorPatoomratana Tuchindaen_US
dc.contributor.authorMihoko Morien_US
dc.contributor.authorKazuro Shiomien_US
dc.contributor.authorTakuya Nihiraen_US
dc.contributor.authorWatanalai Panbangreden_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherKitasato Universityen_US
dc.contributor.otherOsaka Universityen_US
dc.date.accessioned2018-11-09T01:58:38Z
dc.date.available2018-11-09T01:58:38Z
dc.date.issued2014-01-01en_US
dc.description.abstract© 2014, Springer Science+Business Media Dordrecht. The rare actinomycetes strain 2EPS was isolated from soil and analysis of cultural, morphological characteristics, diaminopimelic acid content of its cell wall, and 16S rRNA gene sequence indicates that 2EPS belongs to genus Actinomadura. In addition, neighbor-joining phylogenetic tree also confirmed the relationships of this strain to other members of Actinomadura. A butanol extract with antibacterial activity was purified by reversed-phase chromatography to obtain three bioactive compounds, designated as compounds 1, 2 and 3. The structures of these compounds were determined using spectroscopic analysis (1H-NMR and13C-NMR) and mass spectrometric analysis (HR-TOF-MS). Compounds 1–3 were identified and found to be the same as those included in the Japanese patent number JP 09227587 for spirotetronate antibiotics and are BE-45722A (1), BE-45722B (2) and BE-45722C (3), respectively. All compounds were active against Gram-positive bacteria (Staphylococcus aureus ATCC 25923, Bacillus cereus ATCC 14579, and B. subtilis ATCC 6633) with low MIC values between 0.08 and 5.0 µg/ml. Moreover, both 1 and 3 also exhibited strong activity, with similar MIC values, against Clostridiumperfringens S107 at 0.63 µg/ml and C. difficile 630 at 0.08 µg/ml. These results suggest the identified spirotetronate compounds may have potential in the treatment of Clostridium infections. Overall, this analysis demonstrates that rare actinomycetes are a promising source for discovery of antimicrobial compounds.en_US
dc.identifier.citationWorld Journal of Microbiology and Biotechnology. Vol.31, No.2 (2014), 391-398en_US
dc.identifier.doi10.1007/s11274-014-1792-zen_US
dc.identifier.issn15730972en_US
dc.identifier.issn09593993en_US
dc.identifier.other2-s2.0-84964300473en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/33433
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84964300473&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectImmunology and Microbiologyen_US
dc.titleSpirotetronate antibiotics with anti-Clostridium activity from Actinomadura sp. 2EPSen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84964300473&origin=inwarden_US
Files
Collections
Scopus 2011-2015